Cargando…

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes

HER2-low and ultra-low breast cancer (BC) have been recently proposed as new subcategories of HER2 BC, supporting a re-consideration of immunohistochemical negative scores of 0, 1+ and the 2+/in situ hybridization (ISH) negative phenotype. In the present review, we outline the criteria needed to exa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franchina, Mariausilia, Pizzimenti, Cristina, Fiorentino, Vincenzo, Martini, Maurizio, Ricciardi, Giuseppina Rosaria Rita, Silvestris, Nicola, Ieni, Antonio, Tuccari, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454084/ https://www.ncbi.nlm.nih.gov/pubmed/37628975 http://dx.doi.org/10.3390/ijms241612795

Ejemplares similares

Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents
por: Pizzimenti, Cristina, et al.
Publicado: (2023)

HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach
por: Ieni, A., et al.
Publicado: (2015)

HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies
por: Ieni, Antonio, et al.
Publicado: (2020)

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

Brachyury: A Diagnostic Marker for the Differential Diagnosis of Chordoma and Hemangioblastoma versus Neoplastic Histological Mimickers
por: Barresi, Valeria, et al.
Publicado: (2014)

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2017)

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2019)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni, Antonio, et al.
Publicado: (2016)

Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
por: Ieni, Antonio, et al.
Publicado: (2021)

Unusual localization and clinical presentation of primary central nervous system extranodal marginal zone B‑cell lymphoma: A case report
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category
por: Pizzimenti, Cristina, et al.
Publicado: (2023)

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin
por: Ruggeri, Rosaria M., et al.
Publicado: (2016)

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2018)

Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer"
por: Ieni, Antonio, et al.
Publicado: (2016)

The COVID-19 pandemic: Pathologists support the clinical infectious diseases team
por: Ieni, Antonio, et al.
Publicado: (2021)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress
por: Triulzi, Tiziana, et al.
Publicado: (2013)

Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study
por: Ieni, Antonio, et al.
Publicado: (2022)

Experimental parameters defining ultra-low biomass bioaerosol analysis
por: Luhung, Irvan, et al.
Publicado: (2021)

Hepatomegaly and type 1 diabetes: a clinical case of Mauriac’s syndrome
por: Lombardo, Fortunato, et al.
Publicado: (2019)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Diagnostic relevance of cell block procedure in secondary tumors of the pancreas
por: Ieni, Antonio, et al.
Publicado: (2016)

Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis
por: Ieni, Antonio, et al.
Publicado: (2014)

Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy
por: Moreno, David F., et al.
Publicado: (2021)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation
por: Ieni, Antonio, et al.
Publicado: (2014)

HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study
por: Shi, Jiajie, et al.
Publicado: (2023)

The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
por: Peixoto, Guilherme Andrade, et al.
Publicado: (2021)

HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
por: Popović, Marina, et al.
Publicado: (2023)

Mast Cell Interaction with Neutrophils in Human Gastric Carcinomas: Ultrastructural Observations
por: Ieni, Antonio, et al.
Publicado: (2016)

An Updated Review of Cribriform Carcinomas with Emphasis on Histopathological Diagnosis and Prognostic Significance
por: Branca, Giovanni, et al.
Publicado: (2017)

The Association of Low-To-Moderate Alcohol Consumption with Breast Cancer Subtypes Defined by Hormone Receptor Status
por: Strumylaite, Loreta, et al.
Publicado: (2015)

Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma
por: Lu, Huan, et al.
Publicado: (2020)

Case report on pathogenetic link between gluten and IgA nephropathy
por: Costa, Stefano, et al.
Publicado: (2018)

Reliability of Total Serum IgE Levels to Define Type 2 High and Low Asthma Phenotypes
por: Guida, Giuseppe, et al.
Publicado: (2023)

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer
por: Russo, Alessandro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3c712kq6k9u0cuneguku6498aa